The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome
Open accessAbstract
Significance: Cytokine release syndrome (CRS) is a life-threatening complication induced by hyperinflammatory responses. However, no specific immunotherapies are available for its treatment. In this study, we found that interleukin (IL)-6 signaling plays a crucial role in endothelial cell dysfunction during bacterial and viral CRS. Specifically, we identified that the pathogenesis of CRS in patients with sepsis, acute respiratory distress syndrome, and burns involved the IL-6–mediated production of hyperinflammatory cytokines and plasminogen activator inhibitor-1 (PAI-1), which indicates that IL-6 signaling blockade has potential as a therapy for CRS. We also found that the inhibition of IL-6 signaling by tocilizumab treatment decreased PAI-1 production and alleviated clinical manifestations in severe COVID-19 patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Endothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Endothelial Dysfunction: A Marker of Atherosclerotic Risk
Bonetti, P. O., Lerman, L. O., & Lerman, A. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000051384.43104.fc · Cited by 2,200
The immunopathology of sepsis and potential therapeutic targets
van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P., & Netea, M. G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.36 · Cited by 1,957
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · cited 1×
“Various cytokines, such as interleukin (IL)-6, IL-10, interferon (IFN)-γ, monocyte chemotactic protein-1 (MCP-1), granulocyte-macrophage colony-stimulating factor, tumor necrosis factor (TNF)-α, IL-2, and IL-8, are released during CRS (4, 5).”
BackgroundPierrakos, C., & Vincent, J.-L. (2010) · Critical Care · doi:10.1186/cc8872 · Cited by 1,377
Drotrecogin Alfa (Activated) in Adults with Septic Shock
Ranieri, V. M., Thompson, B. T., Barie, P. S., Dhainaut, J.-F., Douglas, I. S., Finfer, S., Gårdlund, B., Marshall, J. C., Rhodes, A., Artigas, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202290 · Cited by 1,309
Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.1.333 · Cited by 1,173
Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80334-9 · Cited by 1,112
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904 · cited 3×
“The IL-6R antagonist tocilizumab suppresses both classic-signaling and transsignaling pathways (8).”
BackgroundInfluentialSelf-citationThe systemic immune response to trauma: an overview of pathophysiology and treatment
Lord, J. M., Midwinter, M. J., Chen, Y.-F., Belli, A., Brohi, K., Kovacs, E. J., Koenderman, L., Kubes, P., & Lilford, R. J. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60687-5 · Cited by 846
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S., & Remick, D. G. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130327 · Cited by 549
Zegeye, M. M., Lindkvist, M., Fälker, K., Kumawat, A. K., Paramel, G., Grenegård, M., Sirsjö, A., & Ljungberg, L. U. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0268-4 · Cited by 349
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Wang, Z., & Han, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0116-0 · Cited by 273
Inflammation, sepsis, and coagulation.
Esmon, C. T., Fukudome, K., Mather, T., Bode, W., Regan, L. M., Stearns-Kurosawa, D. J., & Kurosawa, S. (1999) · PubMed · Cited by 252
Strategies to improve drug development for sepsis
Fink, M. P., & Warren, H. S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4368 · Cited by 242
Plasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock
Pralong, G., Calandra, T., Glausef, M.-P., Schellekens, J., Verhoef, J., Bachmann, F., & Kruithof, E. K. O. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646614 · Cited by 199
The clinical importance of a cytokine network in the acute phase of sepsis
Matsumoto, H., Ogura, H., Shimizu, K., Ikeda, M., Hirose, T., Matsuura, H., Kang, S., Takahashi, K., Tanaka, T., & Shimazu, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-32275-8 · Cited by 193
Self-citationPlasma Biomarkers for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis*
Terpstra, M. L., Aman, J., van Nieuw Amerongen, G. P., & Groeneveld, A. B. J. (2014) · Critical Care Medicine · doi:10.1097/01.ccm.0000435669.60811.24 · Cited by 169
The soluble interleukin 6 receptor: advanced therapeutic options in inflammation
Rose‐John, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.782 · Cited by 169
Lu, Z., Li, Y., Jin, J., Zhang, X., Lopes-Virella, M. F., & Huang, Y. Q. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.251181 · Cited by 70
Clinical Importance of a Cytokine Network in Major Burns
Matsuura, H., Matsumoto, H., Osuka, A., Ogura, H., Shimizu, K., Kang, S., Tanaka, T., Ueyama, M., & Shimazu, T. (2018) · Shock · doi:10.1097/shk.0000000000001152 · Cited by 38
Self-citation
Cited by
MCP-1: Function, regulation, and involvement in disease
Singh, S., Anshita, D., & Ravichandiran, V. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107598 · Cited by 883
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome
Lv, R., Liu, X., Zhang, Y., Dong, N., Wang, X., He, Y., Yue, H., & Yin, Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01496-3 · Cited by 477
Xu, S.-W., Ilyas, I., & Weng, J.-P. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00998-0 · Cited by 440
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 375
Self-citationVirus-induced senescence is a driver and therapeutic target in COVID-19
Lee, S., Yu, Y., Trimpert, J., Benthani, F., Mairhofer, M., Richter-Pechanska, P., Wyler, E., Belenki, D., Kaltenbrunner, S., Pammer, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03995-1 · Cited by 350
Metadata
- Authors
- Kang, S., Tanaka, T., Inoue, H., Ono, C., Hashimoto, S., Kioi, Y., Matsumoto, H., Matsuura, H., Matsubara, T., Shimizu, K., Ogura, H., Matsuura, Y., & Kishimoto, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2020-08-21
- Volume
- 117
- Issue
- 36
- Pages
- 22351-22356
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3080714364
- Cited by
- 330
- References
- 32
- FWCI
- 15.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.